The salient pathological feature of Azhelmer (1-4) .
occupied by plaques that bind radiolabeled ,BA4 in vitro is dramaticafly larger in AD cortex (23 ± 11%) than in agematched normal controls (<2%). In contrast to the human peptide, rat/mouse BA4 (differing at three positions from human flA4) does not affect the deposition of radiolabeled human SA4. lA4 has no detectable interaction with tachykihn receptors in rat or human brain. The use of radioiodinated 3A4 provides an in vitro system for the qumtitative evaluation of agents or conditions that may inhibit or enhance the growth or dissolution of AD plaques. This reagent also provides an extremely sensitive method for visualizing various types of amyloid deposits and a means for characterizing and locating sites of amyloid peptide binding to cells and tissues.
Alzheimer disease (AD), a widespread progressive dementia affecting a significant fraction of the elderly, is characterized by the presence in brain of numerous extracellular proteinaceous deposits called amyloid on the basis of their staining properties. The extracellular amyloid is deposited both at neuropil and vascular sites, and the density of these deposits in the cerebral cortex and blood vessels correlates positively with the degree of dementia. The principal component of both neuritic and vascular amyloid is ,B-amyloid peptide (13A4), a hydrophobic peptide of 39-43 amino acids that is encoded by a gene for a much larger protein termed the amyloid precursor protein. Neither the processing of amyloid precursor protein to ,BA4 nor the genesis of the amyloid deposits is well understood. The characteristics of f3A4 deposition and the factors that affect it remain key questions in the pathology of AD (1) (2) (3) (4) (5) (6) (7) (8) .
Recent work (9) (10) (11) (12) (13) (14) (15) (16) has suggested that fA4 has biological activities of its own, and the 42-mer or its fragments have been reported to be trophic, toxic, and/or amnestic at various concentrations. BA4 has a considerable tendency to form insoluble aggregates under various conditions (17) (18) (19) (20) (21) (22) and evidence has been presented that the neurotoxicity of 83A4 is related to the aggregation process (13, 14) . A sequence similarity ( (1) (2) (3) (4) .
Radloiodination. Peptides containing tyrosine were radiolabeled by oxidative radioiodination using Na125I and chloramine T and separated from free iodide by reverse-phase adsorption. Peptides not containing tyrosine were first acylated with the N-hydroxysuccinimide ester of 4-hydroxyphenylpropionic acid and then oxidatively radioiodinated as above. Labeled peptides containing methionine were then reduced from sulfoxide to native form with 2-mercaptoeth-Proc. Natl. Acad. Sci. USA 89 (1992) 5463 dpm/,ul (26) (27) (28) . The RP-HPLC separations employed shallow acetonitrile gradients that cleanly separate sulfoxide from reduced methionine and iodinated from noniodinated forms of the peptides. It should be noted that the radioiodinated peptides are not precisely identical in chemical structure to the native peptides.
Tissue. Brain tissue was obtained from normal and AD patients (Table 2 ) <14 h postmortem, frozen on dry ice after collection, and stored below -20°C until use. For filter binding studies, tissue homogenates were prepared by the method of Too and Hanley (29) . Briefly, tissue was homogenized by a Polytron, washed several times with centrifugation in a buffer containing protease inhibitors, and then stored below -20°C until use. For autoradiographic binding studies, unfixed tissue was serially sectioned at 15 ,um and thawmounted onto gelatin-coated slides. Slide-mounted sections were stored at -20°C in closed boxes over desiccant for <3 months before use. Rat brain tissue was removed immediately after sacrifice by decapitation, frozen on dry ice after collection, and stored below -20°C until use.
Homogenate Binding. Membranes (equivalent to =30 mg of tissue) were resuspended in 0.5 ml of 50 mM Tricine (pH 7.5) containing bovine serum albumin (1 mg/ml), 10 mM MnC12, 0.004% bacitracin, 0.0002% chymostatin, 0.0004% leupeptin, and 0.1% dimethyl sulfoxide for 30 min prior to addition of radioligand at 10 pM to 1 nM and various concentrations of unlabeled peptides in the same buffer. After incubating 2 h at room temperature, the homogenates (final volume, 0.575 ml) were filtered through glass fiber filters (Whatman GF/D presoaked for at least 2 h in bovine serum albumin at 1 mg/ml) and rinsed with 25 mM Tricine (pH 7.5). After washing twice with 25 mM Tricine (pH 7.5) at room temperature, radioac- tivity on the filters was measured in a y counter. The signal/noise ratio and specific binding were a function of the density of plaques in the tissue. In a typical experiment with AD tissue and 0.1 nM radioligand, 20 ,000 cpm (10%6) of the 125I-pA4-(1-40) added was bound in the absence of unlabeled peptides, and 10,000 cpm (5%) was bound in the presence of 10 ,uM unlabeled f3A4-(1-40). During the course of the experiments described, no significant degradation or oxidation of the radioligand was detected by RP-HPLC. Tachykinin receptor binding studies were performed in a similar manner (24, 29, 30) .
Autoradiography. Tissue sections were preincubated for 30 min and incubated with radioligand for 2 h under the conditions used for homogenate binding studies except that Tris HCl rather than Tricine was used as buffer. For estimating nonspecific binding, paired serial sections were incubated with radioligand in the presence of a 104-to 106-fold excess of the unlabeled peptide. After incubation with radioligand, the slides were washed with 50 mM Tris-HCI (pH 7.5; four 2-min washes at 4°C) and with distilled water (two 5-sec washes at 4°C), dried at 4°C, and stored in closed boxes over desiccant at room temperature overnight. The fully dried slides were then placed in apposition to film next to radioiodinated standards. After a 1-week exposure at -20°C, outside the plaques and the plaques themselves, but deposition of the radioligand was restricted to the plaques alone.
The sensitivity of detection of plaques with the radioligand far exceeds that of the antibodies we have examined (Fig. 2) .
Amyloid deposits were visualized by 1251-PA4-(1-40) deposition in 5-20o of intra-and extraparenchymal blood vessels in AD brain (Fig. 3) . The cerebrovascular deposits were consistently labeled more intensely than cerebral plaques within the same section. In vessels seen in transverse section (Fig. 3) , the deposition of 8A4 radioligand was not uniform but rather was concentrated in a part of the vesselapparently, the smooth muscle of the tunica media; the endothelium was not labeled. Competition Binding Experiments. All experiments on tissue sections or homogenates included tubes containing identical solutions in the absence of tissue that were monitored for aggregate formation by both filtration and centrifugation. These parallel experiments showed no evidence ofaggregation under the conditions described. Deposition of 125I-PA4-(1-40) onto plaques in both homogenates and sections ofAD cerebral cortex is significantly attenuated by excess unlabeled ,A4-(1-40) and Dutch fBA4-(1-40) (Figs. 1 and 2 ). /3A4-(25-35)-NH2 also competes at much higher concentrations, whereas the free acid f3A4-(25-35)-OH has no detectable activity in this assay.
Rat fA4-(1-40) had no effect on the deposition of 125I-.BA4-(1-40) onto plaques. No significant differences in f3A4 deposition were noted between homogenates and sections of AD tissue or between neuritic and diffuse plaques.
The mammalian tachykinins (23), substance P and neurokinins A and B, and a nonpeptide NK1 tachykinin receptor antagonist, CP-96,345 (25), did not inhibit the deposition of radiolabeled 3A4 onto AD plaques over a broad range of concentration (Fig. 1) .
Saturable binding sites for tachykinin radioligands selective for NK1 and NK3 tachykinin receptor subtypes (30) were present at similar densities in both AD and normal brain tissue (data not shown). Cell types expressing tachykinin binding sites were not identified. Unlabeled tachykinins displaced their radiolabeled analogues at nanomolar concentrations in both tissues. In contrast, there was no displacement of any of the tachykinin radioligands by A4-(1-40), rat ,BA4-(1-40), or Dutch B3A4-(1-40) at up to 30 ,uM. f3A4-(1-40) also failed to displace radiolabeled tachykinins from their binding sites in rat (30) brain homogenates and sections.
Time Course of P3A4-(1-40) Deposition. As quantitated by densitometry of autoradiograms, radiolabeled PA4 deposition from solution onto amyloid plaques was linear for at least several hours. When plaques onto which 125I-f3A4-(1-40) had been deposited for 2 h were incubated in the absence of amyloid peptide, the radiolabeled peptide dissociated from the plaques (Fig. 4) . Thus deposition of 1251-pA4-(1-40) onto plaques is reversible. that binding is not saturable suggests that the vast majority of the sites to which the radioligand binds are not receptors in the usual sense. Instead, the characteristics of this binding are consistent with a steady-state equilibrium between fiA4 on the tissue amyloid plaques and in solution. Thus 1251-#A4- at picomolar concentrations is reversibly deposited onto AD plaques and dissociates when the plaques are exposed to a solution containing no B3A4 (Fig. 4) . The precise nature of the plaque component to which the radioligand binds is not addressed by these experiments.
Under these experimental conditions, the in vitro growth of plaques by deposition of 125I-/3A4-(1-40) proceeds at the lowest concentration of radioligand that can be conveniently quantitated (1-10 pM) . The affinity of (3A4 for the plaques is sufficiently high that deposition is a favorable process even at such dilute concentrations.
Both the classic senile plaques and the diffuse nonneuritic deposits in the cortical grey matter and the vascular amyloid deposits within the walls of the cerebral arteries are capable of in vitro growth by addition of 8A4 from dilute solution. Use of radiolabeled f3A4 detects tissue amyloid with great sensitivity and emphasizes the great density ofamyloid deposits in AD vs. normal tissue ( Table 2) .
.8A4 and Tachykinins. The tachykinin neuropeptides are defined by their C terminus, -Phe-Aaa-Gly-Leu-Met-NH2, where Aaa is an aromatic or aliphatic residue. This conserved C-terminal sequence, including the terminal carboxyamide, is required for essentially all the biological activities of the peptides in the tachykinin family.
Various tachykinin agonists and antagonists had no detectable effect on in vitro growth of AD amyloid (Fig. 1) . Since several experiments failed to detect any interaction between fBA4 and various tachykinin receptors found in normal human and AD brain and in rat brain, 3A4 apparently does not interact with tachykinin receptors under these conditions (data not shown). These results are consistent with the reported structure-activity studies among the tachykinin peptide family that a C-terminal amide is required for activity (23) and argue against the hypothesis (15) that the reported biological activity of PA4 (9) (10) (11) (12) (13) (14) (15) (16) results from its interaction with tachykinin receptors.
Aggregation of pA4 in the Absence of Tissue. Under the conditions of the tissue binding assay described above, there is no detectable aggregation of pA4 in the absence ofplaques. At higher concentrations or in solvents other than those described above, PA4-(1-40) and certain of its fragments can also form aggregates (17) (18) (19) (20) (21) in the absence of nucleating plaques, and the radiolabeled fA4 can be used as a sensitive and convenient monitor of such aggregation. The rate of aggregation of PA4 in tissue free systems is highly dependent on experimental conditions (data not shown).
Implications for AD. The avidity of PA4 for amyloid plaques implies that once a nucleating aggregate of BA4 has formed, even extremely low concentrations of jA4 will support its growth. The reversibility of plaque growth in vitro suggests a steady-state equilibrium between fA4 in plaques and in solution. The in vitro studies described here are consistent with the hypothesis that the plaques themselves (neuritic, diffuse, and vascular) can grow in vivo in the presence of traces of PA4. A similar situation in vivo would imply that an alteration in the processing or degradation of PA4 that increased the extracellular concentration of j3A4 could play a critical role in the genesis of AD (1) and that plaque growth in the brain may be reversible. The spontaneous aggregation of BA4 under certain conditions is likely to be related to the early nucleating events of plaque formation and thus to the neurotoxicity of,A4 (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) and the pathology of the disease. The use of radiolabeled 3A4 provides a convenient model of these processes for further investigation of the role of fA4 in AD. The present study suggests a sensitive and quantitative assay for evaluation of agents and conditions that may alter the growth of amyloid plaques and aid in the search for effective treatments of AD.
